Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2010 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: March 2, 2010
Last updated: June 11, 2010
Last verified: May 2010

RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Ixabepilone may also make tumor cells more sensitive to radiation therapy. Giving radiation therapy with chemotherapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone when given together with radiation therapy to see how well it works in treating patients with high-risk stage III prostate cancer after surgery.

Condition Intervention Phase
Prostate Cancer
Drug: ixabepilone
Procedure: adjuvant therapy
Radiation: intensity-modulated radiation therapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Adjuvant Prostate Irradiation and Ixabepilone For High Risk Prostate Cancer Post-Prostatectomy

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Dose-limiting toxicity (phase I)
  • Maximum-tolerated dose (phase I)
  • Freedom from progression for 3 years (phase II)

Secondary Outcome Measures:
  • Time to biochemical, local and distant failure (phase II)
  • Disease-specific survival (phase II)
  • Overall survival rate (phase II)
  • Adverse events as assessed by NCI CTCAE v. 4.0

Estimated Enrollment: 54
Study Start Date: May 2010
Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Detailed Description:



  • To determine the maximum-tolerated dose and dose-limiting toxicity of ixabepilone in combination with concurrent intensity-modulated radiation therapy in patients with high-risk prostate cancer after prostatectomy. (Phase I)
  • To determine the toxicity profile of this regimen in these patients. (Phase I)


  • To assess freedom from progression in patients treated with this regimen. (Phase II)
  • To assess biochemical failure, local failure, and distant failure in patients treated with this regimen. (Phase II)
  • To assess disease-specific survival and overall survival of patients treated with this regimen. (Phase II)
  • To evaluate acute and late toxicity of this regimen in these patients.

OUTLINE: This is a phase I, dose-escalation study of ixabepilone followed by a phase II study.

Patients undergo adjuvant intensity-modulated radiation therapy once daily, 5 days a week, for 7-9 weeks. Patients also receive concurrent ixabepilone IV over 1 hour on days 1 and 8. Treatment with ixabepilone repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up every 3 months for 1 year, every 6 months for 3 years, and then annually for 6 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Diagnosis of adenocarcinoma of the prostate

    • Must have undergone any common form of prostatectomy (e.g., open, perineal, laparoscopic, or robotic) within the past 2 years
    • T3 disease or positive surgical margins
    • Node negative (N0) and free of distant metastasis (M0) by a bone scan and CT scan or MRI of the pelvis within the past 90 days
    • Considered high-risk disease
  • Gleason score = 7 and post-operative PSA > 0 and ≤ 2 ng/mL OR Gleason score ≥ 8 and post-operative PSA ≥ 0 and ≤ 2 ng/mL
  • Pre-prostatectomy PSA available

    • Range of pre-prostatectomy PSA values not required


  • Zubrod (ECOG) performance status 0-1
  • ANC ≥ 2,000/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 8 g/dL
  • Total bilirubin < 1.5 times upper limit of normal (ULN)
  • AST and ALT < 2.5 times ULN
  • Alkaline phosphatase < 2.5 times ULN
  • Fertile patients must use effective contraception during and for 4 weeks after completion of study therapy
  • Patients with urinary incontinence waiting for stabilization of urinary function after prostatectomy allowed for up to 6 months
  • No CTCv4 peripheral neuropathy (motor or sensory) ≥ grade 1
  • No history of inflammatory colitis including Crohn disease or ulcerative colitis
  • No significant history of psychiatric illness
  • No other invasive malignancy within the past 3 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the oral cavity
  • No severe, active co-morbidity with any of the following:

    • Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
    • Transmural myocardial infarction within the past 6 months
    • Acute bacterial or fungal infection requiring IV antibiotics
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days
    • Immunocompromised patients or AIDS based upon current CDC definition

      • HIV testing not required
  • No history of hypersensitivity reactions to agents containing Cremophor® EL or its derivatives (e.g., polyoxyethylated castor oil)


  • See Disease Characteristics
  • No prior pelvic radiotherapy or radiotherapy for another malignancy that encompasses ≥ 30% of major bone marrow-containing areas (e.g., pelvis or lumbar spine)
  • No prior hormonal therapy for prostate cancer

    • Prior hormonal agents, e.g., finasteride or dutasteride, for benign prostatic hypertrophy allowed
  • No other concurrent adjuvant antineoplastic therapy planned while on this protocol, including the following:

    • Cryotherapy
    • Hormonal therapy
    • Other chemotherapy for prostate cancer

      • Prior chemotherapy for a different type of cancer allowed provided it was administered > 3 years ago
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01079793

United States, Texas
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Clinical Trials Office - Simmons Comprehensive Cancer Center a    866-460-4673; 214-648-7097      
Sponsors and Collaborators
Simmons Cancer Center
National Cancer Institute (NCI)
OverallOfficial: Arlene Thomas Simmons Cancer Center
Principal Investigator: David A. Pistenmaa, MD Simmons Cancer Center
  More Information

Responsible Party: Regulatory Affairs Associate, Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Identifier: NCT01079793     History of Changes
Other Study ID Numbers: CDR0000666842
Study First Received: March 2, 2010
Last Updated: June 11, 2010

Keywords provided by National Cancer Institute (NCI):
adenocarcinoma of the prostate
stage III prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on April 21, 2017